Latest news with #NeuroScientificBiopharmaceuticals
Yahoo
02-08-2025
- Business
- Yahoo
NeuroScientific Biopharmaceuticals (ASX:NSB) jumps 14% this week, though earnings growth is still tracking behind one-year shareholder returns
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock market. When you buy and hold the right company, the returns can make a huge difference to both you and your family. For example, the NeuroScientific Biopharmaceuticals Limited (ASX:NSB) share price is up a whopping 576% in the last 1 year, a handsome return in a single year. Also pleasing for shareholders was the 410% gain in the last three months. The longer term returns have not been as good, with the stock price only 6.4% higher than it was three years ago. We love happy stories like this one. The company should be really proud of that performance! On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last year NeuroScientific Biopharmaceuticals grew its earnings per share (EPS) by 54%. The share price gain of 576% certainly outpaced the EPS growth. So it's fair to assume the market has a higher opinion of the business than it a year ago. The fairly generous P/E ratio of 70.06 also points to this optimism. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). This free interactive report on NeuroScientific Biopharmaceuticals' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further. A Different Perspective We're pleased to report that NeuroScientific Biopharmaceuticals shareholders have received a total shareholder return of 576% over one year. That's better than the annualised return of 1.2% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with NeuroScientific Biopharmaceuticals (including 2 which are potentially serious) . For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Sydney Morning Herald
31-07-2025
- Business
- Sydney Morning Herald
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.
The Age
31-07-2025
- Business
- The Age
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.
The Age
28-07-2025
- Business
- The Age
Strategic CEO hire to drive NeuroScientific stem cell therapy release
NeuroScientific Biopharmaceuticals has made a second heavy-hitting appointment in less than a week, bringing in experienced Melbourne-based executive Nathan Smith as its chief executive officer, as the company gears up for the commercial release of its innovative StemSmart stem cell technology. Smith has extensive experience in cell and gene therapies in senior commercial, operational and strategic roles in Australia and the United States, which should prove invaluable as the company navigates the regulatory and commercial pathways for its innovative StemSmart technology. The company says his deep expertise in good practice manufacturing will be critical for converting the biotechnology startup into a scaled-up commercial stem cell company. NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopgen. StemSmart uses a specific type of stem cell, mesenchymal stromal stem cells (MSC), as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'I was attracted to NSB given the historical success of StemSmart in multiple serious clinical disorders and the clear potential of the technology for further development.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith Adding to the company's ranks of highly credentialled personnel, NeuroScientific announced on Friday that it had also recruited well-regarded Perth-based paediatric haematologist and oncologist Dr Catherine Cole as its chief medical officer. The news of both appointments has continued to fuel a stellar rise in the company's share price, which traded 11.3 per cent higher today to 24.5 cents on the best turnover since April. The company's share price is up 360 per cent since the start of June. Smith was the director of business development at Melbourne's Cell Therapies, which develops and manufactures advanced cell-based therapies and is located within the city's pioneering Peter MacCallum Cancer Centre. He has held key roles at Genzyme Corporation, Mesoblast Inc and GlaxoSmithKline in the US, as well as other leading companies in the cell therapy sector.
West Australian
28-07-2025
- Business
- West Australian
Strategic CEO hire to drives NeuroScientific stem cell therapy release
NeuroScientific Biopharmaceuticals has made a second heavy-hitting appointment in less than a week, bringing in experienced Melbourne-based executive Nathan Smith as its chief executive officer, as the company gears up for the commercial release of its innovative StemSmart stem cell technology. Smith has extensive experience in cell and gene therapies in senior commercial, operational and strategic roles in Australia and the United States, which should prove invaluable as the company navigates the regulatory and commercial pathways for its innovative StemSmart technology. The company says his deep expertise in good practice manufacturing will be critical for converting the biotechnology startup into a scaled-up commercial stem cell company. NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopgen. StemSmart uses a specific type of stem cell, mesenchymal stromal stem cells (MSC), as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. Adding to the company's ranks of highly credentialled personnel, NeuroScientific announced on Friday that it had also recruited well-regarded Perth-based paediatric haematologist and oncologist Dr Catherine Cole as its chief medical officer. The news of both appointments has continued to fuel a stellar rise in the company's share price, which traded 11.3 per cent higher today to 24.5 cents on the best turnover since April. The company's share price is up 360 per cent since the start of June. Smith was the director of business development at Melbourne's Cell Therapies, which develops and manufactures advanced cell-based therapies and is located within the city's pioneering Peter MacCallum Cancer Centre. He has held key roles at Genzyme Corporation, Mesoblast Inc and GlaxoSmithKline in the US, as well as other leading companies in the cell therapy sector. NeuroScientific says that having led programs across their full therapeutic cycle, including pre-clinical development and clinical trials, Smith has extensive experience in navigating regulatory approvals and developing commercial product supplies. Smith said he was excited to help advance the technology and make it accessible to patients with serious and life-threatening conditions. 'I was attracted to NSB given the historical success of StemSmart in multiple serious clinical disorders and the clear potential of the technology for further development,' he said. The high-level executive duo of Smith and Cole join a strong leadership team, which also includes Perth-based haematology medical scientist Dr Marian Sturm, as NeuroScientific's chief scientific officer. Sturm pioneered the use of the MSC used in StemSmart over the past 20 years in her former role as facility director of Royal Perth Hospital's Cell and Tissue Therapies centre. StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special media, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes. The cells have been used many times over the years via early-phase clinical trials, studies and on compassionate grounds, with promising results. Later in the year, the company expects to receive the interim results from its latest compassionate trial involving patients with difficult-to-treat fistulising Crohn's disease, in which an open wound develops from a gut flare-up that extends out to the skin. A successful trial will help the company validate its proprietary StemSmart technology in this patient group, who otherwise have limited treatment options. NeuroScientific has created a bit of a whirlwind this year with its Isopogen acquisition, re-energised leadership team and a $3.5 million capital raise. The funding has handed the company a $7.5 million war chest to support further trials and development and helped it generate plenty of momentum towards its long-term goal of partial or full registration for StemSmart, first up as a Crohn's treatment. Is your ASX-listed company doing something interesting? Contact:
